Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 7 clinical trials
Acromegaly Combination Treatment Study

In this study the investigators will evaluate whether combination low dose somatostatin receptor ligand (SRL) and weekly or daily Pegvisomant will attain equivalent control of serum IGF-1 levels at a lower cost, compared to combination high dose SRL and weekly Pegvisomant. Lower doses of therapy will greatly reduce cost of …

octreotide
pegvisomant
medical therapy
somatostatin
lfts
  • 130 views
  • 04 Oct, 2021
  • 1 location
LAnreotide in Metastatic Pheochromocytoma / PARAganglioma (LAMPARA)

The objectives of this study are: To assess the efficacy of lanreotide given every 4 weeks in participants with advanced or metastatic paraganglioma/ pheochromocytoma. To

adrenal pheochromocytoma
pheochromocytoma
metastatic disease
catecholamines
chromogranin a
  • 0 views
  • 24 Nov, 2021
  • 2 locations
A Trial Aiming to Assess the Safety and Activity of the Combination of Cabozantinib Plus Lanreotide in GEP and NET

A Phase II trial aiming to assess the safety and activity of the combination of cabozantinib plus lanreotide in gastroenteropancreatic (GEP) and thoracic neuroendocrine tumor (NET): The LOLA

edotreotide
somatostatin
cabozantinib
radionuclide therapy
selective internal radiation therapy
  • 0 views
  • 12 Sep, 2021
  • 1 location
A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET

The purpose of this study is to compare the effectiveness and safety of CAM2029 to octreotide LAR or lanreotide ATG in patients with advanced, well-differentiated GEP-NET. Patients who

  • 0 views
  • 18 Dec, 2021
  • 7 locations
Study of Tamoxifen in Well Differentiated Neuroendocrine Tumors and Hormone Receptor Positive Expression

This is a single-arm, unicentric, single-stage clinical study of tamoxifen for patients with well differentiated neuroendocrine tumors and radiological progression with positive (> 1 percent) HR (estrogen and / or progesterone) expression by IHC. It will evaluate if Tamoxifen exerts antitumor action in patients with well differentiated NET and positive …

platelet count
measurable disease
pancreatic net
who 2017
neutrophil count
  • 0 views
  • 03 Feb, 2021
  • 1 location
Asian Investigation of Lanreotide Autogel in the Management of GEP-NETs

Lanreotide Autogel has been established as a standard of care for patients with locally advanced or metastatic GEP-NETs based on the success of CLARINET trial. However, only few patients with

  • 0 views
  • 27 Jan, 2021
  • 1 location
United Kingdom (UK) Patient Preference Study of Somatuline Autogel and Treatment Administration Setting

The aim of the study is to generate real-world evidence to describe the patient experience of administration of Somatuline® Autogel® (lanreotide) in homecare and hospital settings, and the

  • 0 views
  • 17 Dec, 2021
  • 4 locations